ReviewFrontiers in endocrinology2025
Fertility in early breast cancer patients: integrating reproductive planning into oncology care.
Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fertility preservation (FP) and adequate counseling are crucial for young breast cancer patients in the early setting. We provide a brief summary of FP in young breast cancer patients, including current international guidelines, available FP treatments, and the safety of pregnancy. This review explores embryo/oocyte cryopreservation, ovarian tissue cryopreservation (OTC), and gonadotropin-releasing hormone agonists (GnRHa), along with evidence on temporary endocrine therapy interruption to attempt pregnancy. Despite strong recommendations, FP uptake remains low, underscoring the need for timely multidisciplinary counseling. Literature data underline that pregnancy can be considered after treatment, even for hormone receptor-positive and BRCA mutation-positive patients. Reproductive planning should be integrated into the oncologic treatment, balancing oncologic priorities with patients' reproductive desires.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.